GARTH GREY: Open Payments
NPI 1306428792 · OLNEY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$669 in 31 payments from 12 companies in 2025. Trend: 2023 $482 · 2024 $687 · 2025 $669
Food & beverage: $669
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $106 |
| AstraZeneca Pharmaceuticals LP | 5 | $103 |
| PFIZER INC. | 4 | $86 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $64 |
| Lilly USA, LLC | 3 | $59 |
| Amgen Inc. | 3 | $55 |
| ABBVIE INC. | 2 | $51 |
| Dexcom, Inc. | 1 | $41 |
| GlaxoSmithKline, LLC. | 2 | $36 |
| Astellas Pharma US Inc | 1 | $31 |
Products named: NURTEC ODT, XIFAXAN, BREZTRI, MOUNJARO, AIRSUPRA, Wegovy, Dexcom G6 Transmitter, EVENITY.
Industry payments across MD — which companies pay providers there.
